Xiaofei Ni

504 total citations
20 papers, 305 citations indexed

About

Xiaofei Ni is a scholar working on Hematology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Xiaofei Ni has authored 20 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 6 papers in Pathology and Forensic Medicine and 6 papers in Oncology. Recurrent topics in Xiaofei Ni's work include Platelet Disorders and Treatments (12 papers), Autoimmune Bullous Skin Diseases (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Xiaofei Ni is often cited by papers focused on Platelet Disorders and Treatments (12 papers), Autoimmune Bullous Skin Diseases (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Xiaofei Ni collaborates with scholars based in China and Belgium. Xiaofei Ni's co-authors include Jian Suo, Dan Jia, Lei Wang, Yan Chen, Xuan Sun, Ming Hou, Jun Peng, Yu Hou, Lingjun Wang and Tianshu Yu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Xiaofei Ni

17 papers receiving 301 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaofei Ni China 10 154 117 105 91 44 20 305
Janina Jamasbi Germany 11 53 0.3× 140 1.2× 34 0.3× 223 2.5× 49 1.1× 12 387
Renata Pacholczak‐Madej Poland 11 55 0.4× 45 0.4× 100 1.0× 13 0.1× 61 1.4× 46 274
Julie Flynn Australia 12 202 1.3× 58 0.5× 154 1.5× 24 0.3× 51 1.2× 21 343
Robert Martucci Italy 6 23 0.1× 86 0.7× 68 0.6× 127 1.4× 28 0.6× 8 303
Christos Christopoulos United Kingdom 9 104 0.7× 112 1.0× 44 0.4× 32 0.4× 56 1.3× 17 280
Ryszard Bachowski Poland 6 144 0.9× 97 0.8× 19 0.2× 20 0.2× 49 1.1× 17 242
A Gupta United Kingdom 2 71 0.5× 66 0.6× 13 0.1× 32 0.4× 76 1.7× 3 434
Masaaki Lee‐Kawabata Japan 13 86 0.6× 267 2.3× 11 0.1× 50 0.5× 67 1.5× 21 397
Jennifer Bordenave France 8 41 0.3× 91 0.8× 41 0.4× 26 0.3× 263 6.0× 13 371

Countries citing papers authored by Xiaofei Ni

Since Specialization
Citations

This map shows the geographic impact of Xiaofei Ni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaofei Ni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaofei Ni more than expected).

Fields of papers citing papers by Xiaofei Ni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaofei Ni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaofei Ni. The network helps show where Xiaofei Ni may publish in the future.

Co-authorship network of co-authors of Xiaofei Ni

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaofei Ni. A scholar is included among the top collaborators of Xiaofei Ni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaofei Ni. Xiaofei Ni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Yu, Tianshu, Lingjun Wang, Haoyi Wang, et al.. (2025). Effects of orelabrutinib, a BTK inhibitor, on antibody‐mediated platelet destruction in primary immune thrombocytopenia. British Journal of Haematology. 206(4). 1186–1199. 2 indexed citations
4.
5.
Wang, Lingjun, Haoyi Wang, Mingfang Zhu, et al.. (2024). Platelet-derived TGF-β1 induces functional reprogramming of myeloid-derived suppressor cells in immune thrombocytopenia. Blood. 144(1). 99–112. 17 indexed citations
6.
Ni, Xiaofei, Lingjun Wang, Haoyi Wang, et al.. (2022). Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia. Blood. 140(26). 2818–2834. 12 indexed citations
7.
Hou, Yu, Jie Xie, Shuwen Wang, et al.. (2022). Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia. Cellular and Molecular Immunology. 19(7). 764–776. 21 indexed citations
8.
Wang, Haoyi, Tianshu Yu, Ning An, et al.. (2022). Enhancing regulatory T-cell function via inhibition of high mobility group box 1 protein signaling in immune thrombocytopenia. Haematologica. 108(3). 843–858. 10 indexed citations
9.
Ni, Xiaofei, Yajing Zhao, Tianshu Yu, et al.. (2022). Rapamycin Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction in Immune Thrombocytopenia. Blood. 140(Supplement 1). 8404–8405. 2 indexed citations
10.
Ni, Xiaofei, Daqi Li, Chenglu Yuan, et al.. (2022). Single‐dose versus low‐dose rituximab in corticosteroid‐resistant or relapsed ITP: A multicenter, randomized, controlled study. American Journal of Hematology. 97(4). 440–447. 4 indexed citations
11.
Yu, Tianshu, Lingjun Wang, Xiaofei Ni, et al.. (2021). Orelabrutinib, a Selective Bruton's Tyrosine Kinase (BTK) Inhibitor in the Treatment of Primary Immune Thrombocytopenia (ITP). Blood. 138(Supplement 1). 3172–3172. 8 indexed citations
12.
Wang, Lingjun, Li-Zhen Li, Chaoyang Li, et al.. (2021). Significance of anti‐HBc serological status in primary immune thrombocytopenia. British Journal of Haematology. 196(4). 1086–1095. 2 indexed citations
13.
Xu, Pengcheng, Yajing Zhao, Tianshu Yu, et al.. (2021). Atorvastatin restores imbalance of cluster of differentiation 4 (CD4)+ T cells in immune thrombocytopenia in vivo and in vitro. British Journal of Haematology. 201(3). 530–541. 7 indexed citations
14.
Yu, Tianshu, Haoyi Wang, Yajing Zhao, et al.. (2021). Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Advances. 5(20). 4087–4101. 25 indexed citations
15.
Ni, Xiaofei, Dan Jia, Yan Chen, Lei Wang, & Jian Suo. (2019). Is the Enhanced Recovery After Surgery (ERAS) Program Effective and Safe in Laparoscopic Colorectal Cancer Surgery? A Meta-Analysis of Randomized Controlled Trials. Journal of Gastrointestinal Surgery. 23(7). 1502–1512. 121 indexed citations
16.
Zhao, Yajing, Xiaofei Ni, Pengcheng Xu, et al.. (2019). Interleukin-37 reduces inflammation and impairs phagocytosis of platelets in immune thrombocytopenia (ITP). Cytokine. 125. 154853–154853. 15 indexed citations
17.
Ni, Xiaofei, Yanpeng Xing, Xuan Sun, & Jian Suo. (2019). The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials. Clinics and Research in Hepatology and Gastroenterology. 44(2). 211–222. 17 indexed citations
18.
Ni, Xiaofei, Dan Jia, Yuchen Guo, Xuan Sun, & Jian Suo. (2019). The efficacy and safety of enhanced recovery after surgery (ERAS) program in laparoscopic digestive system surgery: A meta-analysis of randomized controlled trials. International Journal of Surgery. 69. 108–115. 27 indexed citations
19.
Ni, Xiaofei, et al.. (2018). The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis. Clinical & Translational Oncology. 21(5). 674–686. 14 indexed citations
20.
Ni, Xiaofei, et al.. (2009). Small molecule pan-bcl-2 inhibitor AT-101 induces apoptosis in NSCLC by up-regulating noxa and enhances antitumor activity of docetaxel or targeted kinase inhibitors. Journal of Clinical Oncology. 27(15_suppl). e14591–e14591. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janina Jamasbi Breakdown of academic impact, for papers by Renata Pacholczak‐Madej Breakdown of academic impact, for papers by Julie Flynn Breakdown of academic impact, for papers by Robert Martucci Breakdown of academic impact, for papers by Christos Christopoulos Breakdown of academic impact, for papers by Ryszard Bachowski Breakdown of academic impact, for papers by A Gupta Breakdown of academic impact, for papers by Masaaki Lee‐Kawabata Breakdown of academic impact, for papers by Jennifer Bordenave
Rankless by CCL
2026